ArticleFrontiers in psychiatry2026
Spectral EEG-guided adaptive neuromodulation for social anxiety disorder, performance-only subtype: a case report.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Social anxiety disorder (SAD) is often complicated by anticipatory anxiety, hyperarousal, and variability in response to first-line treatments such as cognitive behavioral therapy (CBT) and pharmacotherapy. These limitations highlight the need for adjunctive modalities capable of enhancing the magnitude and durability of treatment response. This case report explores outcomes following spectral EEG-guided personalized repetitive transcranial magnetic stimulation (PrTMS) in a patient with SAD, performance-only subtype. Weekly psychometric assessments revealed reductions in social anxiety intensity, avoidance behaviors, and negative self-appraisal, along with improvements in mood and daily function. Symptom changes were quantified using the Liebowitz Social Anxiety Scale (LSAS), Social Phobia Inventory (SPIN), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder 7-Item Scale (GAD-7), and Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Clinical improvements were accompanied by increased alpha band power, decreased delta band power, and an increased alpha-delta ratio on serial spectral resting-state EEGs. Our findings suggest that PrTMS may warrant further investigation as a potential adjunctive treatment for SAD. Further large-scale, blinded, and randomized studies are warranted to validate our observations on the feasibility of PrTMS for SAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.